SCHEMBL26212929

SCHEMBL26212929

O=S(=O)(NCCCl)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.63
ADAMTS4 O75173 2/20 0.63
MMP13 P45452 2/20 0.63
MMP14 P50281 2/20 0.63
ADAMTS5 Q9UNA0 2/20 0.63
CA12 O43570 5/20 0.59
CA1 P00915 5/20 0.59
CA2 P00918 5/20 0.59
CA9 Q16790 5/20 0.59
MMP1 P03956 1/20 0.58
MEP1B Q16820 1/20 0.58
HTT P42858 3/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
PGR P06401 3/20 0.54
ALDH1A1 P00352 4/20 0.52
POLB P06746 1/20 0.52
LMNA P02545 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
FFAR1 O14842 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8881270 0.84 ALDH1A1 (0.68) CA1CA2KMT2AALDH1A1LMNA
SCHEMBL26212913 0.81 MMP2 (0.60) MMP2MMP13MMP14MMP1MEP1B
SCHEMBL4521900 0.80 ALDH1A1 (0.74) MMP2ADAMTS4MMP13MMP14ADAMTS5
SCHEMBL10029061 0.80 MMP2 (0.63) MMP2ADAMTS4MMP13MMP14ADAMTS5
SCHEMBL12499028 0.80 ALDH1A1 (0.75) MMP2MMP13CA1CA2MMP1
SCHEMBL20282176 0.79 MMP2 (0.64) MMP2ADAMTS4MMP13MMP14ADAMTS5
SCHEMBL10029067 0.79 MMP2 (0.64) MMP2ADAMTS4MMP13MMP14ADAMTS5
SCHEMBL10029063 0.79 MMP2 (0.64) MMP2ADAMTS4MMP13MMP14ADAMTS5
SCHEMBL5271298 0.78 MMP2 (0.56) MMP2ADAMTS4MMP13MMP14ADAMTS5
SCHEMBL26212911 0.77 L3MBTL1 (0.56) MMP2MMP14MMP1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115843271-B Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2024-08-13 CN disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed
CN-115843271-A Indole derivatives and their use for the treatment of cancer 克洛德贝纳尔-里昂第一大学 2023-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 MMP2 2564/4885ADAMTS4 3594/4885MMP13 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.